Topical Timolol: a Comparison of Surgical Outcomes

Phase 2 Unknown 30 enrolled Keith G. LeBlanc, Jr, MD

RandomizedParallel-groupSingle-blindTreatment

Summary

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the literature. The investigators will enroll 30 participants in a split scar study who have their skin cancer surgically removed resulting in a linear wound equal to or longer than 4cm. The objective of this randomized study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily greater than or equal to 1.5 cm.

Timeline

Start: 2021-04-07
Primary completion: 2022-09
Completion: 2022-12

Publications

Jeha GM, Dickerson T, Hargrave L, Bao-Loc-Trung M, Prusisz T, Bucher E, Rougelot RC, LeBlanc K Jr. Does Timolol Solution Improve the Appearance of Acute Surgical Wounds After Mohs Surgery? A Split-Scar Clinical Study. Dermatol Surg. 2024 May 1;50(5):481-483. doi: 10.1097/DSS.0000000000004094. Epub 2024 Jan 23. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Timolol	Other / unclassified	0.25 %	Topical

Indications

No indication recorded.